Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Posts Smaller Q2 Revenue, Loss

NEW YORK, July 24 - Israeli bioinformatics company Compugen today reported contracted second-quarter revenue growth, thinned R&D spending and a slightly narrowed net loss.

 

Total revenue for the period ended June 30 was $2.8 million, down a touch from the $2.9 million Compugen posted during the same time last year. Though revenue from sales and services fell to $2.3 million from $2.8 million year over year, revenue for R&D in the current second quarter increased to $473,000 from $130,000 one year ago, the company said.

 

However, second-quarter R&D spending fell to $3 million from $3.8 million last year, Compugen said. This cutback likely helped the company reign in it its net loss for the second, which stood at $2.8 million, or $.11 per share, compared with $3.9 million, or $.15 per share, year over year.

 

Compugen said it had about $33.3 million in cash, cash equivalents, and short-term investments as of June 30.

 

The company has scheduled an investor conference call for 10:00 a.m. Eastern time.

                       

Click here for more information.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.